DERWENT-ACC-NO: 2005-108785

DERWENT-WEEK: 200512

COPYRIGHT 2006 DERWENT INFORMATION LTD

TITLE: Method for production of complex-specific egg yolk antibody containing various antibodies including anti-helicobacter pylori igy, anti-salmonella enteritidis igy and anti-staphylococcus aureus IgY

Basic Abstract Text (1):

NOVELTY - Production of a complex-specific egg yolk(IgY) antibody containing various antibodies including anti-helicobacter pylori IgY, anti-salmonella enteritidis IgY and anti-staphylococcus aureus IgY is provided. Therefore, functional eggs containing water-soluble complex-specific IgY are produced to increase human health and develop health foods industry.

Basic Abstract Text (2):

DETAILED DESCRIPTION - Production of a complex-specific egg yolk antibody(IgY) containing various antibodies comprises the steps of: preparing antigens including Helicobacter pylori antigen, Helicobacter pylori urease antigen, r-glutamyltranspeptidase antigen, vacuolating cytotoxin(VacA) antigen, catalase antigen, Salmonella enteritidis antigen, Staphylococcus aureus antigen, Staphylococcus aureus exotoxin antigen, and ETEC(enterotoxigenic Escherichia coli) exotoxin antigen; administering the antigens into a 19 week-old laying hen, a 21 week-old laying hen and a 25 week-old laying hen, sequentially; and isolating IgY using ionic water of pH 3-6 or pH 9-11 with one or more of glucose, maltose, sucrose, sorbitol, trehalose and mannitol.

DOCUMENT-IDENTIFIER: US 5510241 A

TITLE: Method of testing for the presence of Salmonella serotypes expressing Salmonella enteritidis fimbrial antigen (SEFA) and reagents therefore

Abstract Text (1):

A method of testing for the presence of Salmonella serotypes S. enteritidis and S. dublin is provided. Novel monoclonal antibodies are used to detect the presence of an epitope specific for these serotypes in cultures which have been grown on selected media which enhance the expression of said epitope in fimbrial sites. Test kits utilizing the antigen or its epitopic parts, antibodies and/or the media are further provided.

CLAIMS:

- 1. A method of testing a sample for the presence of microorganisms for Salmonella serotypes expressing Salmonella enteritidis fimbrial antigen (SEFA) comprising the steps of:
- (a) exposing a sample suspected of containing the microorganisms, or SEFA to an antibody which specifically binds to the antigen specifically bound by the monoclonal antibody secreted by ECACC 90101101 or ECACC 90121902 or an antibody which specifically binds the epitope bound by the monoclonal antibody secreted by ECACC 90101101 or ECACC 90121902;
- (b) detecting antibody-antigen specific binding, wherein antigen-antibody specific binding is indicative of the presence of microorganisms selected from the group consisting of S. enteritidis, S. dublin, S. moscow and S. blegdam, and the absence of antibody-antigen specific binding is indicative of the absence of S. enteritidis.
- 2. A method of testing for the presence of a previous or current infection with Salmonella serotypes expressing SEFA comprising the steps of:
- (a) exposing said SEFA to a biological specimen obtained from a subject suspected of having a current or a previous Salmonella infection, wherein said SEFA specifically binds an antibody which specifically binds to the antigen specifically bound by the monoclonal antibody secreted by ECACC 90101101 or ECACC 90121902 or an antibody which specifically binds the epitope bound by the monoclonal antibody secreted by ECACC 90101101 or ECACC 90121902; then
- (b) detecting antibody-antigen specific binding wherein the presence of antibody-antigen specific binding is indicative of the presence of a previous or current Salmonella infection with microorganisms selected from the group consisting of S. enteritidis, S. dublin, S. moscow and S. blegdam, and the absence of antibody-antigen specific binding is indicative of the absence of a previous or current infection with S. enteritidis.
- 3. A method of determining whether a Salmonella serotype belongs to either a group consisting of S. enteritidis, S. moscow and S. blegdam or a group consisting of S. dublin, S. moscow and S. blegdam comprising the steps of:
- (a) exposing a sample suspected of containing at least one of said Salmonella serotypes to an antibody which specifically binds to the antigen specifically bound by the monoclonal antibody secreted by ECACC 90101101 or ECACC 90121902 or an antibody which specifically binds the epitope bound by the monoclonal antibody secreted by ECACC 90101101 or ECACC 90121902 and then detecting antibody-antigen binding, wherein antibody-antigen specific binding is indicative of the presence of a

Salmonella serotype of either one of the groups; and

- (b) exposing a further sample of said sample suspected of containing at least one of said Salmonella serotypes to an <u>antibody</u> which specifically binds S. <u>enteritidis</u> but not S. dublin and detecting <u>antibody</u> antigen specific binding wherein <u>antibody</u> antigen specific binding indicates the presence of S. <u>enteritidis</u>, S. moscow or S. blegdam.
- 4. A method as claimed in claim 1 further comprising step (c) exposing a further sample of said sample suspected of containing at least one of said Salmonella serotypes to an <u>antibody</u> which specifically binds S. dublin but not S. <u>enteritidis</u> and detecting <u>antibody</u>-antigen specific binding wherein <u>antibody</u> antigen specific binding indicates the presence of S. dublin, S. moscow or S. blegdam.
- 6. A method a claimed in claim 5 wherein the culture medium is selected by screening candidate culture media for the ability to support the expression of SEFA by S. enteritidis or a SEFA-expressing strain of S. dublin, wherein the screening comprises culturing a sample of S. enteritidis or a SEFA-expressing strain of S. dublin in or on the candidate culture medium and exposing a second sample obtained from the culturing step to an antibody which specifically binds to the antigen specifically bound by the monoclonal antibody secreted by ECACC 90101101 or ECACC 90121902 or an antibody which specifically binds the epitope bound by the monoclonal antibody secreted by ECACC 90101101 or ECACC 90121902 and then detecting antibody-antigen specific binding wherein antibody-antigen specific binding is indicative of culture medium having the ability to support the expression of SEFA.


WEST Search History



DATE: Friday, June 02, 2006

Hide?	<u>Set</u> <u>Name</u>	Query	<u>Hit</u> Count
	DB=P	GPB, USPT, USOC, EPAB, JPAB, DWPI, TDBD; PLUR=YES; OP=OR	
	L1	enteritid\$.ti,ab,clm.	330
	L2	L1 and (yolk or egg or sera or serum)	144
	L3	L2 and (immune or immunoglobulin or igg or ig-g or ig-y or antiigg or anti-igg or antiigy or antibodies or antibody or polyclonal or polyclonal)	101
	L4	L1 same (immune or immunoglobulin or igg or ig-g or ig-y or antiigg or antiigg or antiigg or antiigy or antibodies or antibody or polyclonal or polyclonal)	34
	L5	L4 and 12	21

END OF SEARCH HISTORY



Search Results - Record(s) 1 through 34 of 34 returned.

☐ 1. 20040086517. 24 Jun 03. 06 May 04. Method of modulating the immune system in an animal to an antigen. TenHuisen, Kevor S., et al. 424/184.1; 604/890.1 C12Q001/68 A61K039/00 A61K009/22.
2. 20030185856. 27 Nov 02. 02 Oct 03. Method for the production of the egg containing antipathogenic bacteria specific antbodies(igy) and the yogurt and ice cream containing the igy. Lee, Nam-Hyung, et al. 424/203.1; 119/300 A61K039/116 A01K031/19.
☐ 3. <u>20030118630</u> . 07 Dec 01. 26 Jun 03. Immune modulation device for use in animals. Cerami, Anthony, et al. 424/443; 442/123 A61K009/70 B32B027/12 A61F013/00.
4. <u>20030068812</u> . 21 Mar 02. 10 Apr 03. Immune modulation device for use in animals. TenHuisen, Kevor S., et al. 435/283.1; 435/345 435/5 436/548 C12Q001/70 C12M001/00 C12N005/06 C12N005/16 G01N033/53.
5. <u>6958158</u> . 21 Mar 02; 25 Oct 05. Immune modulation device for use in animals. TenHuisen; Kevor S., et al. 424/424; 424/184.1 424/423 424/426 604/19 604/93.01. A61F002/00 A61K009/00 A61K039/00 A61M031/00.
☐ 6. <u>6495334</u> . 20 May 99; 17 Dec 02. Recombinant Sef14 fimbrial protein from Salmonella. Rajashekara; Gireesh, et al. 435/7.32; 424/139.1 424/163.1 424/164.1 424/184.1 424/185.1 424/190.1 424/234.1 424/258.1 435/252.8 435/4 435/7.1 435/7.2 435/7.35 530/300 530/350. G01N033/554 .
7. 6136325. 19 Feb 97; 24 Oct 00. Live vaccine constituting minor risk for humans. Linde; Klaus, et al. 424/258.1; 424/93.1 424/93.4 424/93.48. A61K039/112 A01N063/00.
8. <u>5961985</u> . 14 May 97; 05 Oct 99. Vaccine and serum for endotoxin associated disease immunization and treatment, detoxified endotoxin, and bacterial mutant. Sprouse; Ronald F., et al. 424/258.1; 424/147.1 424/184.1 424/193.1 424/197.11 424/257.1 424/278.1. A61K039/112.
9. <u>5807694</u> . 07 Sep 95; 15 Sep 98. Detection of salmonella <u>enteritidis</u> and other pathogenic microorganisms and monoclonal <u>antibody</u> useful therefor. Zawistowski; Jerzy. 435/7.35; 435/174 435/243 435/252.8 435/7.1 435/7.2 435/7.32. G01N033/569 G01N033/53 C12N001/20.
10. <u>5641492</u> . 27 Sep 93; 24 Jun 97. Vaccine and serum for endotoxin associated disease immunization and treatment, detoxified endotoxin, and bacterial mutant. Sprouse; Ronald F., et al. 424/258.1; 424/184.1 424/193.1 424/197.11 424/278.1 424/776 424/93.2. A61K039/112 A61K039/39 A61K031/715 A61K045/00.
11. <u>5510241</u> . 25 May 95; 23 Apr 96. Method of testing for the presence of Salmonella serotypes expressing Salmonella enteritidis fimbrial antigen (SEFA) and reagents therefore. Thorns; Christopher J. 435/7.3; 435/7.35 530/350 530/387.1 530/388.4 530/389.5 530/391.1 530/391.3. G01N033/53 C07K014/255 C07K016/00.
12. <u>JP407250673A</u> . 02 Feb 95. 03 Oct 95. BACTERIAL MUTANT . SPROUSE , RONALD F, et al. C12N001/20; A61K039/112.

13. WO002053179A1. 31 Mar 01. 11 Jul 02. THE METHOD FOR THE PRODUCTION OF THE EGG CONTAINING ANTI-PATHOGENIC BACTERIA SPECIFIC ANTIBODIES (IGY) AND THE YOGURT AND ICE CREAM CONTAINING THE IGY. LEE, NAM-HYUNG, et al. A61K039/02;.
☐ 14. EP000540063A1. 15 Dec 92. 05 May 93. Hyperimmune serum for endotoxin associated disease, detoxified endotoxin and bacterial mutant GARNER, HAROLD F, et al. 424/258.1. A61K039/112; A61K039/39 A61K039/40 C08B037/00 C12N001/20.
☐ 15. <u>WO009206197A1</u> . 01 Oct 91. 16 Apr 92. METHOD OF TESTING FOR SALMONELLA. THORNS. CHRISTOPHER JOHN. C12N001/20; C12N015/31 C12N015/62 C12P021/08 G01N033 '569.
☐ 16. WO2005026129A. New 4,6-disubstituted aminopyrimidine derivatives are protein kinase inhibitors useful for the treatment of e.g. asthma, diabetes, rheumatic diseases, AIDS, rhinitis and chronic obstructive pulmonary diseases. BACKES, A, et al. A61K031/505 C07D239/42 C07D239/48 C07D401/04 C07D401/12 C07D403/12 C07D405/12 C07D409/04 C07D409/12 C07D409/14 C07D413/12 C07D417/12.
☐ 17. RU 2248396C. New recombinant plasmid DNA pcDNA-TCI providing expression of artificial gene TCI in eukaryotic cells for construction of a live DNA-vaccine against human immunodeficiency virus. AGAFONOV, A P, et al. A61K039/112 A61K039/21 C12N001/21 C12N015/48 C12N015/63 C12N001/21 C12R001:42.
18. <u>KR2004083748A</u> . Method for production of complex-specific egg yolk <u>antibody</u> containing various <u>antibodies</u> including anti-helicobacter pylori igy, anti-salmonella <u>enteritidis</u> igy and anti-staphylococcus aureus IgY. BAEK, B S, et al. C07K016/02.
19. <u>US 6537552B</u> . New fusion protein for preventing or treating diseases susceptible to the effects of cellular immune responses, e.g. infection, cancer or AIDS, comprises an immune enhancing molecule and an immunogenic molecule. MAHAIRAS, G G, et al. A01N063/03 A61K039/02 A61K039/04 A61K045/00 C12N001/00.
20. KR2002086814A. Production of egg containing special immunoglobulin against E. coli, salmonella enteritidis, salmonella typhimurium and transmissible gastroenteritis virus. BAEK, B S, et al. A61K039/395.
21. WO 200253179A. Producing egg containing antipathogenic bacteria specific antibodies, for preventing gastritis, by immunizing hens with Escherichia coli, Helicobacter pylori, Salmonella enteritidis and Salmonella typhimurium. BAEK, B, et al. A01K031/19 A01K067/00 A01K067/027 A23C009/13 A23C009/152 A23G009/02 A23L001/00 A23L001/24 A23L001/305 A23L001/32 A61K039/02 A61K039/116 A61K039/395 A61K039/40 A61P001/04 C07K001/30 C07K001/34 C07K016/12 C07K016/46.
☐ 22. KR2002056452A. Egg yolk antibody against salmonella. KIM, J U. C07K016/02.
23. KR2002032772A. Specific egg yolk antibody(igy) against salmonella. KIM, J U. C07K:)16/02.
24. KR2001081232A. Method for encapsulating egg yolk immunoglobulins using polymer sensitive to acidity. KIM, G S, et al. A61K009/48.

25. WO 200078995A. New method for the specific detection of Salmonella enteritidis infections of poultry comprises contacting a biological sample with antigenic fragments of S. enteritidis fimbrial and/or flagellin proteins. KWANG, H, et al. C07K(14/255 C12Q001/10.
☐ 26. <u>US20020128381A</u> . Immobilizing polysaccharides with keto-carboxy group to solid surface e.g. Or detection of bacterial infections from Gram-negative bacteria. BOAS, U, et al. C07H001/00 C07H003/04 C07H003/06 C07H007/02 C07H015/00 C08B037/00 C12P019/04 C12Q001/02 G01 \ 033/53 G01N033/543 G01N033/544 G01N033/569 G01N033/573.
27. WO 9949026A. New attenuated bacteria useful as vaccines for protecting against infections. CHATFIELD, S N. A61K039/00 A61K039/02 A61 €339/095 A61K039/10 A61K039/102 A61K039/106 A61K039/108 A61K039/112 A61K€48/00 A61P031/04 C12N000/00 C12N001/20 C12N001/21 C12N001:20 C12N015/01 C12N015/03 C12N015/31 C12P001/00 C12P021/04 C12R001/19 C12R001:19 C12N001/20 C12R001:19 C12N001/21 C12R001:19 C12N001/20 C12F001:19.
☐ 28. WO 9945120A. A new attenuated Salmonella useful as a vaccine against Salmonella, Shigella or E. coli. GALYOV, E E, et al. A61K035/74 A61K039/112 A61K048/00 C07K014/255 C07K016/12 C12N001/21 C12N001/36 C12N015/31 C12N015/74 C12Q001/68 G01N033/53.
29. WO 9852605A. Immunopotentiating composition - comprises an antigen or antigen inducing substance and an immunoactive substance. BRANDON, M.R., et al. A61K000/00 A61K009/00 A61K039/39 A61K047/30 A61K047/34 A61K047/42.
30. <u>US 5807694A</u> . Immunoassays for detecting pathogenic microorganisms in materials - especially Salmonella in eggs. ZAWISTOWSKI, J. C12N001/20 G01N033/53 G01N033/569.
31. <u>JP 04211613A</u> . Oral compsn. for prevention and treatment of opportune infection - contains antibody against bacterial antigen in milk obtd. from cow sensitised by the antigen e.g. Staphylococcus or Streptococcus etc A61K035/20 A61K039/395 A61K039/40 A61P031/04 C07K015/06.
32. <u>FP 551324B</u> . Detection and identification of salmonella - by using monoclonal antibodies to detect epitope(s) of these serotypes in culture. THORNS, C J, et al. C07H021/04 C07K007/06 C07K007/08 C07K013/00 C07K013/00 C07K014.255 C07K015/12 C07K016/00 C12N001/20 C12N005/20 C12N015/31 C12N015/62 C12P021/09 C12Q001/68 G01N033/53 G01N033/56 G01N033/569.
33. <u>DE 3439345C</u> . Use of hyper-immune milk - for treatment of cardiovascular and pulmonary diseases, lowering blood lipid and stimulating lung macro:phage. BECK, L R, et al. A23C009/146 A23 C009/20 A23C021/00 A23L001/30 A24B015/30 A61K035/20 A61K038/17 A61K039/39 A61K039/395 A61K047/00 C07G017/00 C07K001/36 C07K014/47 C07K015/06.
34. <u>DE 2157148A</u> . Immunising agents contg boid a and/or antilipoid a antibodies for immunotherapy against all enterobacteraceae-induced diseases. A61K023/00 A61K035/16 A61K037/22 A61K039/40 C12K005/00.
Generate Collection Print
Term Documents

IMMUNE	164567
IMMUNES	40
IMMUNOGLOBULIN	55824
IMMUNOGLOBULINS	29964
IGG	62083
IGGS	1962
IG-G	67
IG-GS	3
IG-Y	26
IG-IES	0
IG-YS	1
(L1 SAME (IMMUNE OR IMMUNOGLOBULIN OR IGG OR IGG OR IG-G OR IG-Y OR ANTIIGG OR ANTI-IGG OR ANTI-IGY OR ANTIIGY OR ANTIBODIES OR ANTIBODY OR POLYCLONAL OR POLY-CLONAL).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	34

There are more results than shown above. Click here to view the entire set.

Prev Page Next Page Go to Doc#